KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Gross Margin: 2009-2025

Historic Gross Margin for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to 86.52%.

  • Vertex Pharmaceuticals' Gross Margin rose 68.00% to 86.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 86.28%, marking a year-over-year increase of 16.00%. This contributed to the annual value of 86.11% for FY2024, which is 110.00% down from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' Gross Margin is 86.52%, which was up 0.30% from 86.25% recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Gross Margin high stood at 88.85% for Q1 2021, and its period low was 85.38% during Q4 2023.
  • Its 3-year average for Gross Margin is 86.65%, with a median of 86.52% in 2025.
  • Its Gross Margin has fluctuated over the past 5 years, first soared by 79bps in 2022, then crashed by 231bps in 2023.
  • Vertex Pharmaceuticals' Gross Margin (Quarterly) stood at 88.06% in 2021, then crashed by 37bps to 87.70% in 2022, then slumped by 231bps to 85.38% in 2023, then grew by 8bps to 85.46% in 2024, then surged by 68bps to 86.52% in 2025.
  • Its last three reported values are 86.52% in Q3 2025, 86.25% for Q2 2025, and 86.90% during Q1 2025.